ZURICH (Reuters) - Swiss drugmaker Roche Holding AG confirmed its forecast of rising sales and profit for this year as it posted an 8 percent rise in third-quarter sales helped by growing momentum of its new breast cancer drugs.
The world's largest maker of cancer drugs said quarterly sales rose to 11.57 billion Swiss francs ($12.63 billion), compared with the average analyst forecast of 11.54 billion francs in a Reuters poll.
($1 = 0.9160 Swiss francs)
(Reporting by Caroline Copley)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp